Breaking News
Get 45% Off 0
Investors lost 37% by missing this ONE signal 😵
Read now

Zacks Investment Research Zacks Investment Research

Zacks Investment Research's Opinion & Analysis.
Featured here: a complete archive of all posts and research produced by Zacks Investment Research, including current material.
Constellation Brands Concludes Divesture Of Ballast Point By Zacks Investment Research - Mar 02, 2020

Constellation Brands, Inc. (NYSE:STZ) declared that it completed the agreement with Kings & Convicts Brewing Co. to sell the Ballast Point brand and related assets for an undisclosed amount. The...

Best & Worst Performing Stocks In Coronavirus Outbreak By Zacks Investment Research - Mar 02, 2020

The coronavirus outbreak and its subsequent impact on corporate profit margins and the global economy continue to dominate the headlines. U.S. stocks endured their worst weekly slide on Feb 28 since...

Ingevity (NGVT) Authorizes Share Repurchase Worth $500M By Zacks Investment Research - Mar 02, 2020

Ingevity Corporation (NYSE:NG) announced that its board approved an authorization to buy back up to $500 million of its outstanding common stock.Additionally, the company plans to purchase up to...

Construction Spending Hits 2-Year High In January: 5 Picks By Zacks Investment Research - Mar 02, 2020

The U.S. construction sector has sustained its 2019 momentum so far this on the back of continued improvement in residential and non-residential construction, and a revival in infrastructure demand....

AutoZone (AZO) Beats Q2 Earnings Estimates By Zacks Investment Research - Mar 02, 2020

AutoZone (NYSE:AZO) came out with quarterly earnings of $12.39 per share, beating the Zacks Consensus Estimate of $11.87 per share. This compares to earnings of $11.49 per share a year ago. These...

Plug Power (PLUG) To Report Q4 Earnings: What To Expect? By Zacks Investment Research - Mar 02, 2020

Plug Power Inc. (NASDAQ:PLUG) is scheduled to release fourth-quarter 2019 results on Mar 5, before market open.The company delivered weaker-than-expected results in three of the last four quarters,...

Steel Stocks Are Bleeding: Will Coronavirus Bring More Pain? By Zacks Investment Research - Mar 02, 2020

Shares of U.S. steel companies are getting punished amid the coronavirus outbreak, which has been spreading fast outside China of late. The lethal respiratory virus has taken a heavy toll on most...

Buy 5 Blue-Chip Stocks At A Bargain To Tap Stellar Dow Rebound By Zacks Investment Research - Mar 02, 2020

On Mar 2, the Dow has recovered some lost ground on news that several major central banks worldwide are likely to take initiatives to stimulate the global economy, which is currently grappling with...

Stimulus Hopes Triumph Over Virus: 5 Top ETF Picks For March By Zacks Investment Research - Mar 02, 2020

After the February chills, global markets sprung back to life at the start of March. As the global markets have been dealing with the coronavirus and Wall Street has entered into correction mode in...

Moving Average Crossover Alert: Tenneco By Zacks Investment Research - Mar 02, 2020

Tenneco Inc. (NYSE:TEN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average...

Moving Average Crossover Alert: Cabot By Zacks Investment Research - Mar 02, 2020

Cabot Corporation (NYSE:CBT) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving...

Moving Average Crossover Alert: Momo By Zacks Investment Research - Mar 02, 2020

Momo Inc. (NASDAQ:MOMO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front. Recently, the 50 Day Moving Average...

AbbVie's Venclexta Combo Fails In Late-Stage Leukemia Study By Zacks Investment Research - Mar 02, 2020

AbbVie (NYSE:ABBV) announced that a phase III study — VIALE-C — evaluating a combination regimen of its blood cancer drug, Venclexta (venetoclax), failed to meet primary endpoint. The...

Albemarle (ALB) Announces Hike Of 5% In Quarterly Dividend By Zacks Investment Research - Mar 02, 2020

Albemarle Corporation (NYSE:ALB) announced that its board has declared an increase in the quarterly dividend.The revised dividend of 38.5 cents per share is roughly 5% higher than the previous...

Continue with Apple
Continue with Google
or
Sign up with Email